Maze Therapeutics’ (MAZE) “Outperform” Rating Reiterated at Wedbush

Posted by George Bondi on Sep 26th, 2026

Wedbush restated their outperform rating on shares of Maze Therapeutics (NASDAQ:MAZE – Free Report) in a research report released on Wednesday morning,Benzinga reports. The brokerage currently has a $48.00 price objective on the stock.

A number of other equities analysts have also recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Monday. Wall Street Zen cut shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. BTIG Research reaffirmed a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a report on Tuesday. Citigroup started coverage on Maze Therapeutics in a research report on Wednesday. They issued a “buy” rating and a $50.00 price target for the company. Finally, TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Maze Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $63.40.

Get Our Latest Stock Analysis on MAZE

Maze Therapeutics Trading Down 0.6%

MAZE stock opened at $26.05 on Wednesday. The firm has a fifty day moving average price of $27.12 and a 200 day moving average price of $29.02. Maze Therapeutics has a fifty-two week low of $21.95 and a fifty-two week high of $53.65. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The firm has a market cap of $1.45 billion, a PE ratio of -10.34 and a beta of 2.17.

Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, hitting the consensus estimate of ($0.76). Sell-side analysts anticipate that Maze Therapeutics will post -2.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Maze Therapeutics

In other news, CMO Harold Bernstein sold 16,142 shares of the business’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $27.61, for a total transaction of $445,680.62. Following the completion of the sale, the chief marketing officer directly owned 16,142 shares of the company’s stock, valued at approximately $445,680.62. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $27.34, for a total transaction of $205,050.00. Following the completion of the transaction, the insider owned 26,250 shares in the company, valued at approximately $717,675. The trade was a 22.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 191,459 shares of company stock valued at $5,263,539 in the last quarter. 5.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Maze Therapeutics

Several large investors have recently added to or reduced their stakes in MAZE. TRV GP IV LLC purchased a new stake in Maze Therapeutics in the 2nd quarter valued at about $133,502,907. ARCH Venture Management LLC purchased a new position in shares of Maze Therapeutics during the second quarter worth approximately $122,983,582. BlackRock Inc. bought a new stake in shares of Maze Therapeutics during the second quarter valued at approximately $104,525,000. Jupiter Topco LLC bought a new stake in shares of Maze Therapeutics during the second quarter valued at approximately $101,764,000. Finally, Alphabet Inc. bought a new stake in shares of Maze Therapeutics during the second quarter valued at approximately $41,435,000.

Maze Therapeutics News Roundup

Here are the key news stories impacting Maze Therapeutics this week:

Positive Sentiment: Citigroup issued bullish coverage. A correction clarified that Citi initiated Maze Therapeutics with a “Buy” rating and a $50 price target, implying substantial upside from recent levels. Citi subsequently upgraded the stock to “Strong Buy.” Correction: Citigroup Initiates Maze Therapeutics at Buy With $50 Price Target
Positive Sentiment: Additional analysts also see significant upside. BTIG initiated coverage with a “Buy” rating and a $50 target, while HC Wainwright reaffirmed its “Buy” rating and maintained a $110 target—more than four times the recent share price. BTIG Initiates Maze Therapeutics at Buy With $50 Price Target HC Wainwright Reaffirms Buy Rating
Positive Sentiment: Wedbush rated the company “Outperform.” The additional constructive view reinforces the broader analyst optimism surrounding Maze’s prospects. Maze Therapeutics Earns Outperform Rating from Wedbush
Neutral Sentiment: Reported short interest was zero shares. The September 24 report listed no shares sold short and a 0.0-day short-interest ratio. This could reduce evidence of bearish positioning, although the figure may reflect a reporting or data issue given the accompanying reference to a large increase in short interest. Maze Therapeutics Shares Moved, So What Is Driving Attention Now?

Maze Therapeutics Company Profile

(Get Free Report)

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.